Veracyte, Inc. (VCYT)
被高估基本面
71
价格
$46.08
市值
$3.70B
第一部分 · 这家公司值多少
概览
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$562M
最近12个月（截至2026/6/30）
净利润
$114M
最近12个月（截至2026/6/30）
自由现金流
$127M
股东权益合计
$1.31B
负债合计
$96M
流动比率
9.16
利息覆盖率
-
债务/EBITDA
0.51
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$36.94
当前价格
$46.08
安全边际
-24.7%
公允价值区间
$24.01 - $49.87
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
32.89
ROE
5.1%
市净率（P/B）
2.67
P/FCF
22.30
毛利率
71.7%
ROIC
5.9%
盈利能力雷达图
价值创造（经济护城河）
ROIC
5.9%
WACC
15.4%
ROIC − WACC
-9.5 pp
ROIC 低于资本成本：公司每投入一美元都在毁灭价值。
基本面分析标准
通过（20）
- EPS shows upward trend
- Price CAGR 18.93%
- ROIC 5.9%
- Gross Margin 71.7%
- P/FCF 22.30
- P/B Ratio 2.67
- Debt/Equity ratio
- Operating Margin 18.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 8.6%
- Revenue Growth 5Y 34.5%
- Analyst Consensus 84% Buy
- Earnings Surprise avg 90.4%
- Earnings Quality (OCF/NI) 1.56
- Net Margin Trend 20.4% vs 5.5%
- Piotroski F-Score 8/9
未通过（4）
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 3.9%
不可用（3）
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-评分
财务状况强健
盈利质量
高质量：盈利有现金流支撑
股权稀释
正在发行新股，稀释所有权
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Marc A. Stapley | CEO & Director | 55 |
| Ms. Rebecca Chambers | Executive VP & CFO | 47 |
| Dr. Phillip G. Febbo M.D. | Chief Scientific & Medical Officer | 59 |
| Ms. Annie McGuire | Executive VP, General Counsel & Head of Market Access | 45 |
| Dr. John Leite Ph.D. | Global Chief Commercial Officer | 53 |
| Dr. Keith Gligorich Ph.D. | Senior Vice President of Global Operations | - |
| Mr. Jonathan Wygant | VP & Chief Accounting Officer | 54 |
| Dr. Kevin Richard Haas Ph.D. | Chief Development & Technology Officer | 40 |
| Mr. Steven French | Senior VP & Chief Information Officer | - |
| Ms. Kelly Gura | Director of Investor Relations | - |
审计风险
2
董事会风险
2
薪酬风险
5
股东权利风险
4
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for VCYT, sourced from Markets Gazette.
- 2/25/2026NEUTRALVeracyte (VCYT) Q4 2025 Earnings Call Transcript
Investors are keenly awaiting the transcript of Veracyte Inc.'s (VCYT) Q4 2025 earnings call, scheduled for February 25, 2026. While the announcement of such an event is standard for publicly traded companies, the current unavailability of the actual transcript content prevents any in-depth analysis of the financial data, future outlook, or strategic decisions discussed. The eventual release of these details will be crucial for understanding the company's performance and projections, potentially influencing market sentiment and investment decisions. Without this information, the market remains in a holding pattern, awaiting further clarity.
via Markets Gazette